Shots:

• Following the completion of a P-I program- the company plans to initiate P- II studies to evaluate ITI-1284 ODT-SL for the treatment of behavioral disturbances in dementia- dementia-related psychosis and certain depressive disorders in the elderly
• The P-I single and multiple ascending dose studies in healthy volunteers including elderly subjects aged >65yrs. evaluated the safety- tolerability and PK of ITI-1284 and reported no SAEs in either age group
• TI-1284 is a deuterated form of lumateperone- delivered sublingually as an ODT-SL and offer pharmacologic benefits and ease of use for patients- particularly in elderly populations

 ­ Ref: GlobeNewswire | Image: The Science of Parkinson's